Related Experiment Video
Updated: May 24, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
938
Modality Imbalance? Dynamic Multi-Modal Knowledge Distillation in Automatic Alzheimer's Disease Recognition.
IEEE Journal of Biomedical and Health Informatics
|March 3, 2025
Summary
This study introduces Dynamic Multi-Modal Knowledge Distillation (DMMKD) to improve Alzheimer's disease (AD) detection from conversations. DMMKD effectively addresses modality imbalance, significantly enhancing diagnostic accuracy in multi-modal machine learning models.
Area of Science:
- Artificial Intelligence
- Computational Neuroscience
- Medical Informatics
Background:
- Alzheimer's disease (AD) is the most common dementia, requiring early detection for better patient outcomes.
- Machine learning models using speech and text show promise for automated AD detection.
- Existing multi-modal approaches struggle with modality imbalance, leading to suboptimal performance.
Purpose of the Study:
- To propose and evaluate a novel Dynamic Multi-Modal Knowledge Distillation (DMMKD) approach.
- To address the modality imbalance challenge in multi-modal AD detection.
- To improve the accuracy and robustness of automated Alzheimer's disease identification.
Main Methods:
- Developed a Dynamic Multi-Modal Knowledge Distillation (DMMKD) algorithm.
- DMMKD dynamically identifies dominant and weak modalities for targeted knowledge distillation.
- Employed inter(cross)-modal and intra-modal distillation to balance learning speeds.
Main Results:
- DMMKD demonstrated substantial performance improvements over standard multi-modal approaches.
- Relative accuracy gains of 15.4% on the ADReSSo dataset and 10.9% on the ADReSS-M dataset were observed.
- Achieved state-of-the-art accuracies of 91.5% (ADReSSo) and 87.0% (ADReSS-M).
Conclusions:
- The proposed DMMKD effectively mitigates modality imbalance in multi-modal learning for AD detection.
- DMMKD significantly enhances diagnostic accuracy compared to existing methods.
- This approach offers a promising solution for improving early Alzheimer's disease identification.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
Dementia
87
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
87

